Fig. 1: ORR in subgroups according to baseline characteristics.

*Smoking history was missing in two patients. ^†Identified at baseline (investigator or independent review). ^‡Patients who tested positive by both methods are included in both sets; testing by both methods was not a requirement for study entry. 1L first line, 2L second line, 2L+ second or later line, BM brain metastases, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status; L+ METex14 skipping detected in liquid biopsy, METex14 MET exon 14, ORR objective response rate, T+ METex14 skipping detected in tissue biopsy.